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Abstract 
Heart failure is a prevalent chronic disease that contributes to many hospitalizations that may not 
always be necessary. Evidence supports that patients who present to the Emergency Department 
in fluid overload can be treated in the outpatient setting when only IV diuretic is warranted. Both 
decreases in costs and improved outcomes have been reported, yet there has been little 
movement toward providing outpatient diuresis versus hospitalization. The purpose of this DNP 
project was to evaluate the feasibility of an outpatient option for IV diuretic therapy for patients 
with acute decompensated heart failure experiencing symptoms of fluid overload. This 
descriptive study involved a retrospective chart review and took place at a large academic 
medical center. The objectives were to describe a random sample of patients that utilized an ED 
for IV diuretic therapy due to fluid overload from January 1, 2018 to December 31, 2018. 
Providers were interviewed and themes were identified to summarize their perspectives. Data 
analysis was performed using descriptive and correlational statistics. Significant differences were 
found between the LOS groups and post-ED cardiology follow-up rates (2(1) = 4.059, p=0.044), 
LOS groups and number of comorbidities (t(8)=-3.628, p=0.000), and number of ED visits and 
missed follow-up cardiology visits (U=554.5, p=0.003). Inconsistencies in documentation of 
instructions and medications were noted. Interview themes surrounded issues with continuity of 
care in this population of heart failure patients. There is a need for more synchronized transitions 
from the hospital to outpatient setting. Those with shorter LOS, less comorbidities, and more 
consistent follow-up may benefit from outpatient IV diuretic therapy. Future research should 
focus on best practice for more coordinated care and ways to engage patients with heart failure. 
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 5 
Evaluating the Feasibility for Outpatient IV Diuretic Therapy for Patients with 
decompensated Heart Failure 
 
Heart failure (HF) is a significant health issue affecting an estimated six million people in 
the United States (Jackson et al 2018). The etiology is multi-focal leading to dysfunction of the 
lining of the heart, the cardiac valves, or the cardiac vasculature. This chronic cardiac illness can 
lead to exacerbations caused by fluid overload resulting in repeated emergency department (ED) 
visits and hospitalizations for diuretic therapy (Collins et al, 2015; Chamberlain et al, 2017). 
These visits are costly and, when hospitalized, can lead to poor outcomes. Identifying patients 
who present in fluid overload that could be managed with outpatient diuresis has been suggested 
(Ota et al, 2013; Storrow et al, 2014). The purpose of this DNP project was to evaluate the 
feasibility of an outpatient option of intravenous (IV) diuretic therapy for patients with acute 
decompensated HF experiencing symptoms of fluid overload.  
Background 
The prevalence of HF is expected to increase 46 percent by year 2030 (AHA, 2017). This 
is due to a variety of factors, such as better medical advances and improved survival rates after 
myocardial infarction. The aging of the U.S. population, along with their medical problems, i.e. 
diabetes, obesity, hypertension, further contributes to the burden of HF (AHA, 2017). It is 
imperative to understand this disease process to improve outcomes and lessen the consequences 
of HF.  
HF is a chronic, progressive illness that is classified by the severity of symptoms 
experienced by the individual and its’ impact on daily life. The pathophysiology of HF centers 
on the inability of the heart to adequately contract to support body processes (Delgado et al, 
2016). The risk for HF increases with uncontrolled hypertension, poorly managed diabetes, post-
myocardial infarction, as well as any condition that impacts the structure and function of the 
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myocardium (Tackling & Borhade, 2019). Management of these conditions can minimize the 
severity of cardiac dysfunction. Treatment goals are dependent on patients’ understanding of 
their disease process, medication compliance, and lifestyle modifications (Diaz et al, 2011; 
Heldenreich et al, 2013). Nonadherence to treatment leads to the symptoms well-recognized as 
exacerbations of HF.   
The diagnosis of acute decompensated HF is based primarily on clinical signs and 
symptoms (Yancy et al, 2013; Collins et al, 2015; Kaur, & Clark, 2015). Symptoms of fluid 
overload include dyspnea, swelling, weight gain, and fatigue. The mainstay of treatment for an 
exacerbation is diuretic therapy. Initial management of congestion may include titration of oral 
diuretic medications but can often require intravenous (IV) diuretic therapy. The 2013 American 
College of Cardiology Foundation/American Heart Association (ACC/AHA) HF guidelines 
direct providers to treat patients with significant fluid overload early with IV diuretic therapy and 
if necessary, in the ED (Yancy et al, 2013).  
The prognosis for patients with HF can be improved through medical therapy 
optimization and adherence to specific lifestyle modifications. These therapies include 
adjustment of certain medications (angiotensin converting enzyme (ACE) inhibitors, beta 
receptor blockers, diuretics, among others), monitoring edema, obtaining daily weights, and 
following salt and fluid restrictions (Unverzagt et al, 2016). The factors that can affect treatment 
nonadherence include demographic influences, lack of transportation or social support, financial 
difficulties, and misunderstanding about the disease process (Shah et al, 2015). Improved 
adherence to disease management guidelines have been shown to decrease likelihood of 
hospitalization and improve morbidity and mortality. 
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The economic impact of HF on the healthcare system is significant and continues to 
increase. It is the leading cause of hospitalizations for older adults, many of which are considered 
preventable (Jackson et al, 2018; Storrow et al, 2015). In the United States, HF utilizes more 
Medicare dollars than any other diagnosis. Currently, its estimated that HF costs are greater than 
$30 billion and will increase to $70 billion by the year 2030 (Dunley et al., 2010). The majority 
of these costs are directly associated to hospital expenses, which average more than $14,000-
$30,000 per person per year (Heldenreich et al, 2013; Jackson et al, 2018; Kilgore et al, 2017). It 
is important to identify factors that contribute to HF exacerbations that lead to hospitalization.  
Healthcare systems must explore ways to reduce the financial burden of HF. This 
includes finding avenues to improve patient adherence to salt and fluid restrictions, as well as 
medication compliance. Further, shifting treatments for HF exacerbations from the ED or 
inpatient setting to the outpatient setting can reduce costs and may be a viable option.  
Review of Literature  
In 2014 alone, HF exacerbations accounted for over one million ED visits, one million 
hospitalizations and over 80,000 deaths (Castello et al., 2017; Jackson et al, 2018). The majority 
of patients with HF that present to the ED (up to 80 percent) will be admitted to the hospital 
(Collins et al., 2013; Storrow et al., 2014). The reasons for this include lack of outpatient options 
for diuretic therapy, provider discomfort in discharging home, and lack of unclear risk 
stratification (Collins et al, 2013, Castello et al., 2017).  
The majority of patients with HF that present to the ED simply need decongestion with 
IV diuretic therapy (Lazkani & Ota, 2012; Ota et al, 2013; Storrow et al, 2014, Hebert et al, 
2011). Although some patients require more intensive therapies, approximately 50 percent that 
present to the ED do not need any interventions other than decongestion (Collins et al., 2013). 
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Further, hospitalizations have not correlated to overall improvement in this condition and 
alternatives to hospitalizations must be explored.  
There have been attempts to decrease the number of patients with HF that are admitted to 
the hospital by creating observation units (OUs) within the ED (Collins et al., 2013). These 
interventions are now complicated by an increasing burden of patients and worsening 
overcrowding among EDs. It is important that interventions to improve the quality of life for 
those with HF be shifted outside of the acute care setting. When patients with HF experience 
acute decompensations that result in hospitalizations, their quality of life becomes poorer and 
their risk of mortality increases (Castello et al., 2013; Storrow et al, 2014). This illustrates the 
need for a different approach to the management of certain aspects of HF disease.      
Hospitals are attempting to decrease HF-related admissions by focusing on interventions 
that can smoothly transition care from the inpatient to the outpatient setting. These interventions 
center on providing coordinated care, medication support and disease education to avoid 
preventable readmissions (AHRQ, 2015; Feltner et al, 2014). Disease-specific management 
programs take a variety of forms, some of which allow access to IV diuretics on an outpatient 
basis (Hebert et al, 2011; Pacho et al, 2017). Allowing access to this option in the outpatient 
setting could decrease hospital admissions and ED utilization for diuretic therapy by patients 
with decompensated HF. 
The potential for cost savings for shifting HF-related treatments from the inpatient to 
outpatient setting could be over $600 million (Ota, Beutler, Gerkin, Weiss, Loli, 2013). Patients 
that receive IV diuretics in an ambulatory location have been shown to decrease ED utilization 
and hospitalizations (Lazkani & Ota, 2012; Ota et al, 2013; Storrow et al, 2014, Hebert et al, 
2011). Healthcare systems must begin to place emphasis on outpatient treatment options for HF 
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exacerbations. There is a need to monitor the effect that an outpatient diuretic infusion clinic 
could have on HF related hospital admissions and ED utilization. Before this association can be 
further examined, it is important to identify the characteristics of the HF population that utilize 
the ED for treatment.  
The purpose of this DNP project was to evaluate the feasibility of an outpatient option of 
intravenous (IV) diuretic therapy for patients with acute decompensated HF experiencing 
symptoms of fluid overload. The specific aims of this project were to:  
(1) Identify the total number of patients who present to an urban, tertiary ED between 
January 1, 2018 and December 31, 2018 requiring IV diuretics, 
(2) Identify the demographics of a randomly selected sample of these patients, 
(3) Examine the comorbidities and severity of HF within the sample, 
(4) Identify the number of patients of the sample that are admitted to an inpatient unit 
from the ED for IV diuresis,  
(5) Explore the relationship between length of stay (LOS) and comorbidities and 
adherence to Cardiology appointments of those that were admitted from the sample for IV 
diuretics, 
(6) Examine the sample’s clinic utilization and recorded adherence to treatment plan prior 
and after the ED visit within the project period, 
(7) Identify the number of patients within the sample who were readmitted within 30 days 
of discharge, 
 (8) Identify ED and cardiology providers’ perceptions regarding the scope of the 
problem and its potential causes of the problem. 
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Theoretical Framework 
Theoretical Frameworks are used in healthcare to solve problems using a systematic 
approach (Peterson et al., 2019). The Social Ecological Model (SEM) is a framework that can 
help communities understand the impact that certain factors have on a process of concern. This 
model was developed to help define the dynamic relationship between individuals and their 
environment (Sallis, Owen, & Fisher, 2008; CDC, 2013). Because health is influenced by 
community and individual factors, this approach can help identify interventions that address all 
determinants of health.  
The SEM is a framework that examines determinants of health and interventions at the 
individual and population levels, with the goal of creating an environment conducive to change 
(CDC, 2013). The SEM of health promotion defines the different levels of influence: individual, 
interpersonal, organizational, community and policy (Sallis, Owen, & Fisher, 2008; CDC, 2013). 
Interventions are more likely to be effective when they address all of these determinants.   
The different levels of the SEM were considered while examining the factors that may 
have contributed to fluid overload symptoms resulting in ED utilization for the project 
population. Individual factors that were assessed included race, gender, age, dietary and 
medication compliance, and outpatient care utilization. Interpersonal factors that were analyzed 
included marital status or the availability of a support system for their disease burden. 
Disposition of care after the initial ED encounter, length of stay, and discharge care instructions 
were organizational factors that were examined. Location of the patient’s primary address was 
gathered to assess for a relationship between the project population and their community.  
Current policies within the organization were assessed for ambulatory management of 
acute decompensations of HF. There was no existing policy in place to guide the management of 
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IV diuretic therapy in the outpatient setting. Interest was expressed by cardiology and ED 
providers to further explore the opportunity of establishing an outpatient IV diuresis program.  
Methods 
Design 
This project was a descriptive study designed to explore the characteristics of patients 
with HF who present to the ED for management of symptoms of decompensated HF.  A 
retrospective chart review of 100 randomly selected patients who presented to the ED with 
symptoms of HF was conducted to determine their demographics, co-morbidities, disposition, 
and outpatient clinic utilization. Providers from the ED and cardiology services were asked to 
participate in a structured interview to identify their perceptions about the scope and potential 
causes of the problem. In addition, they were asked their opinion on the feasibility of an 
outpatient option for IV diuretic therapy. This chart data was inclusive of patients seen in the ED 
between January 1, 2018 to December 31, 2018. Provider interviews were conducted after 
completion of data collection.  
Setting 
This project took place at a large urban academic medical center in central Kentucky. The 
affiliated hospital is a 945 bed acute care facility with access to a number of specialties, 
including cardiology. The ED is a level one trauma center with a 104 beds with a sister hospital 
that has 180 beds and 20 bed ED. For the provider interviews, all were conducted in the 
providers’ private office or in secluded area of ED.  
Sample 
Following IRB approval from the University of Kentucky, the Center for Clinical and 
Translational Science generated a list of all patients who presented to the ED with a diagnosis of 
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HF that received IV diuretics in the project period (January 1, 2018 – December 31, 2018). The 
following ICD-10 codes were used for identifying patients with heart failure: I50.1: Left 
ventricular failure, unspecified, I50.2: Systolic (congestive) heart failure,  I50.3: Diastolic 
(congestive) heart failure,  I50.4: Combined systolic (congestive) and diastolic (congestive) heart 
failure, I50.8: Other heart failure, and I50.9: Heart failure, unspecified. Patients who had Left 
Ventricular Assist Devices, were on chronic milrinone infusions, received dialysis or were under 
the age of 18 were excluded. Patients were also excluded if they died during hospitalization or 
were discharged to hospice.  
Providers included for the interviews consisted of those who work in the ED and 
cardiology services. An email was sent to providers explaining the purposes of the interview and 
amount of time necessary for completion. Consent was obtained and participation was voluntary. 
A total of 5 providers consented for the interview. No student providers were included. Only 
attending physicians, nurse practitioners, and physician assistants were eligible to complete 
interviews.  
Congruence of Project to Organization’s Mission 
This project supported the hospital’s mission to provide the most advanced patient care 
for the region. Intrinsic within that mission is the goal of offering services that are cost-effective 
and lead to the best patient outcomes. This project helped to identify where resources could be 
shifted form an inpatient to an outpatient environment. Further, the mission centers on 
encouraging the development novel services that can be disseminated to the medical community 
to improve care.  
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Facilitators and Barriers to Implementation 
The stakeholders for this project included those providers who care for patients with HF.  
Their input was critical in understanding the concerns and liability they may find with treating 
HF in an outpatient setting. Many may find it easier to admit a patient, rather than risk the 
potential complications associated with outpatient diuresis. Concerns about the logistics of 
developing an outpatient option for diuretic therapy include space and personnel. It is essential to 
avoid getting focusing on those details without first understanding the extent of the issue.   
Hospital administrators also have a vested interest in this issue. The desire to reduce 
unnecessary hospitalization, avoid readmissions within 30 days, and facilitate the patient 
experience falls under their prevue. Presenting an un-biased view of the problem is essential, as 
well as presenting data to support another approach to treating HF. The financial benefits of 
outpatient IV diuresis must be emphasized. Insurance companies, along with hospital billing, 
would likely support this shift of care. Including these parties in the discussion is critical and 
would help influence hospital administration to further support this transition.   
Patients may be both supporters and barriers to the implementation of outpatient IV 
diuretic therapy. This approach may be different to what they have experienced in the past. HF 
exacerbations are stressful situations and patients and/or their families may not be receptive to a 
new treatment approach. One aspect that may help in overcoming their fears will be to ensure 
that adequate outpatient follow-up. This circles back to the need for providers’ support. If the 
provider is not supportive, the patients and hospital administration will less likely be agreeable.  
Data Collection 
For the sample of patients, data was obtained through the hospital’s electronic medical 
record. All patients included in the sample were given a unique study number for de-
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identification purposes. A crosswalk table that linked the study number to their MRN was 
created and kept separately from the study data on an encrypted, password-protect desktop 
computer located in the office of Emergency Management at UK. See Appendix A for Data 
Collection tool. All collected data was organized on an electronic spread sheet, secured using 
RedCap. 
All eligible providers were sent an email (See Appendix B) to participate in the 
interview. See Appendix C that was used to obtain consent from providers. A structured 
interview lasting 10-15 minutes was conducted at a time and place of the providers’ choice. See 
Appendix D for the Interview guide. All providers were de-identified, except for their practice 
area. Data was presented in aggregate form based on their area of service.  
Data Analysis 
Descriptive statistics were used to describe the demographics of the population, including 
frequency distributions, standard deviations, and means. Correlational statistics were used to 
explore relationships between most recent clinic utilization and presentation to ED. Level of 
significance was set at p ‘less than or equal to’ 0.05. For the interviews, common themes were 
identified with comparisons between the services.  The average length of stay in hospital days 
will be calculated. Analysis was conducted in SPSS version 22. 
Results 
 A total of 448 patients met the inclusion criteria within the project period. From this 
population, 100 patients were randomly selected for project purposes. The following statistical 
analysis center on these 100 patients.  
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Sample Characteristics 
Sample characteristics including age, gender, race, marital status, and home location were 
collected and reported in Appendix E. The mean age of sample was 66 years, with a range of 25-
90 years. The sample was equally distributed between male and female genders (n=49, n=51, 
respectively). The majority of the sample was Caucasian (74%), with Black the other prominent 
ethnicity (22%). More than half of the sample lived within the same county as the hospital 
(63%). Slightly less than fifty percent reported being married (47%) with the remaining patients 
reported as being single (13%), divorced (13%), or widowed/separated (27%).  
Heart Failure Characteristics  
For the sample population, Ejection Fraction (EF), comorbidities, and lab values on 
initial encounter to the ED were collected. EF was defined as preserved (55% or greater) and 
reduced (less than 55%). The majority (74 %) had reduced EF of less than 55 percent.  
A list of the comorbidities for the sample group is found is Appendix F. The mean 
number of comorbidities was six, with a range of three to 13. The following comorbidities were 
analyzed for the sample group but were not specifically reported because they were cited in less 
than 10 percent of the sample: Cancer, Cirrhosis, Congenital Heart Defects, Dementia, Hepatitis 
C, Intravenous Drug Abuse, Organ Transplant, Peripheral Vascular Disease, and Coronary 
Artery Bypass Graft (CABG). The notable lab markers obtained from the initial ED encounter 
were the NT-proBNP, Glomerular Filtration Rate (GFR), and Hemoglobin A1C. The mean of the 
NT-pro BNP was 8088 with the range from 164 to 52391 pg/mL. The mean GFR was 46 
mL/min with a range from 6-60mL/min. The average Hemoglobin A1C was 6.56 percent with a 
range of 5 to 13 percent. All collected lab markers were included in Appendix G.   
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Disposition, Length of Stay, and Readmissions 
The disposition of the patients was reported as discharged from ED, admitted to hospital, 
or admitted for observation. The majority of the sample were admitted to the hospital (87%), 
with 13 percent either discharged from the ED or admitted for 24-48 hour observation. 
The average LOS was 4.5 days, but there were outliers that drove the mean higher. Almost 20 
percent of the sample population had a previous ED encounter and HF admission within 30 days 
of the initial encounter date.  
 Two groups were formed based on LOS: patients with LOS two days or less (45%) and 
patients with length of stay three days or greater (55%). No differences were found between LOS 
groups and age, pre-ED appointment rates for cardiology providers. There was a significant 
difference found between the LOS groups and post-ED cardiology follow-up rates (2(1) = 
4.059, p=0.044). Those patients with LOS two days or less were more likely to keep their 
follow-up appointments, unlike those with LOS greater than three days. 
The number of comorbidities also differed between the two LOS groups. Those with LOS 
three days or greater had significantly more comorbidities (t(8)=-3.628, p=0.000). The 
comorbidities that were significantly more present in the three days or greater LOS group were 
chronic pain (p=0.048), mood disorder (p=0.017), pulmonary hypertension (p=0.023), renal 
disease (p=0.044), and thyroid disease (p=0.049). There were significant differences in systolic 
blood pressures and LOS groups (t(98)=2.24, p=0.027).There were no other significant 
associations found between the collected lab values and LOS groups.  
For the group that had a previous 30-day HF readmission, there was no association 
between a 30-day readmission and the total number of comorbidities (t(98)=0.486, p=0.628). 
Specific comorbidities were examined to see if there were any associations with 30-day HF 
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readmissions, but no significant associations were found in this sample. There was no significant 
association found between 30-day HF readmissions and either LOS group (2(1) = 1.576, 
p=0.209). 
Follow-up  
Follow-up appointment attendance with a cardiology provider was collected before and 
after their ED encounter. For the pre-ED Cardiology appointments, 58 percent had been seen six 
months prior to their ED visit, with half of those seen within a month before their ED visit. A 
third of the sample either cancelled or no-showed to their appointment prior to their ED visit. For 
the post-ED Cardiology visits, 31percent were seen within less than a month, 13 percent of the 
sample were seen between two to four months, while 33 percent cancelled or no showed to their 
follow-up appointment.  Data on primary care provider (PCP) appointment attendance could not 
be gathered for most of the sample as they had a provider outside of the health system in which 
this project took place. There was no association found between those patients that missed their 
pre-ED cardiology provider appointments and those that missed their post-ED cardiology 
provider appointments.  
Though the visit reasons could not be collected for all encounters, 95 percent of the 
patients went to the ED between three to six times in 2018. There was no significant difference 
found between the total number of ED visits in 2018 for patients that missed their pre-ED 
cardiology appointments compared to those that kept appointments (U=1004.5, p=0.690). There 
was a significant difference found between the number of ED visits for those that missed their 
post-ED cardiology visits (U=554.5, p=0.003). Patients that did not attend follow-up 
appointments had a greater number of ED visits per year. Those who did not attend appointments 
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had a median of 4 total ED visits compared to those that did attend, who had a median of two 
total ED visits.  
There was no association between pre-ED cardiology appointment attendance and 30 day 
HF readmissions (2 (1)=0.063, p=0.802 & 2 (1)=0.027, p=0.868, respectively), nor was there a 
significant difference between 30 day HF readmissions post-ED cardiology appointment 
attendance (2 (1)=0.651, p=0.420 & 2 (1)=0.397, p=0.529, respectively). No significant 
difference was found between 30 day HF readmissions and LOS days (U=720.5, p=.665).  
Discharge Instructions 
Discharge information from hospital or ED discharge was collected and categorized only 
for those that had an attended follow-up appointment. For these patients, the majority saw their 
cardiology provider (61%) after their ED/hospital encounter, 16 percent saw their PCP, and 23 
percent saw both their cardiology provider and their PCP. The remaining 40 percent either did 
not keep their follow-up appointment or requested an outside provider. For the patients that did 
attend a post-ED/hospital visit with their cardiology provider, the ED/hospital visit was 
addressed in 80 percent of those visits.     
The documentation of ED discharge instructions was examined for this group and topics 
were formed. The most common recommendations at ED or hospital discharge were provider 
medication compliance (93%) and follow-up (89%). Other recommendations included a heart 
healthy diet (39%), sodium restriction (31%), monitoring weight (24%), and fluid restriction 
(20%).  
Information about the medications for the sample population were collected at the time of 
their ED/hospital discharge and at the time of their first follow-up appointment. Appendix H is a 
summary of the most common medication classes patients were prescribed.  No patients were 
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noted to be prescribed a Non-steroidal Anti-Inflammatory Drug (NSAID) or home oxygen. 
When comparing prescribed medications at time of discharge and then at their follow-up 
appointment, the two lists often did not match. It was not clear whether changes were made.  
Provider Interviews 
 A total of five providers were interviewed to assess perceptions regarding the scope of 
and causes of HF exacerbations. Three ED physicians and two cardiology providers participated 
in the interviews. Similarities and differences in the providers’ opinions were noted regarding the 
characteristics that may lead to exacerbations in this population and potential for improvements 
in care.  
 Providers saw a variable number of patients with HF that were in need of IV diuretic 
therapy per week, with the ED providers noting more incidences. Providers identified a number 
of factors that contributed to exacerbations that require IV diuretics. They reported: 
noncompliance with medication or dietary treatment plan, number of comorbid conditions 
(hypertension, myocardial infraction, valvular disease), inability to get in touch with their HF 
provider, or the “cyclical nature of the disease.”  
Use of the ED for exacerbations was also explored. From the perspective of cardiology 
providers, patients were referred to the ED for IV diuretic therapy if they were hemodynamically 
unstable (extreme blood pressures, low oxygen saturation), had poor renal function, were 
experiencing extreme shortness of breath, or were unable to perform activities of daily living. 
They reported “exhausting efforts to keep patients out of the ED by titrating oral mediation 
[regimens]” as tolerated. One cardiology provider felt that the nature of the disease often 
necessitates ED utilization or hospital admission.  
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 The decision to admit patients from the ED to the hospital was difficult for Cardiology 
and ED providers. Most noted that the decision to keep patients in the hospital was based on the 
underlying etiology of the exacerbation; i.e. was the cause from medication noncompliance or 
due to hypertensive crisis or myocardial infarction. Clinical symptoms that necessitated hospital 
admission included hypoxia, labored breathing, significant edema, worsening renal function, 
significant lab marker elevations or electrolyte abnormalities, and questionable social support. 
Exacerbations with mild symptoms caused by dietary or medication noncompliance could be 
discharged home from the ED.    
 The use of the ED for the evaluation and treatment of HF exacerbations does impact the 
flow within the ED. ED providers and Cardiology providers acknowledged the impact on patient 
flow within the ED. One ED provider had previous experience at a similar hospital setting that 
did have an outpatient infusion center for IV diuretic therapy for HF patients. In that setting, “it 
[significantly] helped decrease unnecessary visits” to the ED and inpatient setting. There was an 
expressed interest with exploring this service within the institution’s providers.  
Inadequate communication between Cardiology and the ED was identified as an issue 
within the current system. When a patient presents to the ED with a HF exacerbation, the ED 
“reinvent[s] the wheel every time they refer to cardiology” to discuss the care of a HF patient. 
The inpatient providers often aren’t familiar with the patient, their history, previous lab values, 
or treatment plan. 
 Opinions on the potential for a population of HF patients to be seen in an outpatient IV 
diuretic clinic were gathered. These opinions varied, but three of the five providers believed most 
patients sent to the ED could be seen in an outpatient setting for IV diuresis. Concerns among all 
providers regarding an outpatient option for IV diuretic therapy were logistical issues. 
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Establishment of clear guidelines would be needed to be able to identify reasons for 
exacerbations, how and who could make referrals to the service, who would be ultimately 
assume liability for complications, and the availability of resources to support both providers and 
patients.  
One cardiology provider stated that there is a specific interest in “those [patients] that 
were [admitted to hospital] for less than a 48 hour period.” There is a strong indication that these 
patients “could be managed as an outpatient.” The providers offered criteria that could be used 
for an outpatient treatment for IV diuresis. They cited the need for hemodynamic stability, ability 
to ambulate safety, established cardiology provider in the same system, viable transportation, 
stability of certain lab values (that they do not define), and adequate patient health literacy. This 
was interpreted as patients that could weigh themselves, verbalize knowledge of their 
medications, and understanding of disease process.  
 Improving the continuity of care by maintaining strong follow-up with a primary HF 
provider among this patient population was a common theme. among all providers. It was 
difficult for ED providers to consider discharging a patient due to uncertainty of outpatient 
follow-up plan. There was significant concern over liability. Both provider disciplines believe 
there are gaps in providing continuity of care. Providers noted issues in the current system to 
include a lack of standardized communication between Cardiology and the ED.  
Discussion 
The overall goal of this project was to examine if there was a population of HF patients 
that could have their exacerbations managed with IV diuretic therapy in an outpatient setting. 
The results illustrated some known and new information about this population. There is the 
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potential for a group of patients in this sample to be managed in an outpatient setting based on 
LOS, comorbidities, and clinical factors.   
Similar to what has been reported in the literature, these results show that patients with 
HF utilize the ED frequently, have variable outpatient follow-up, and have an increased risk of 
30 day readmissions (Hasegawa, Tsugawa, Camargo, & Brown, 2014). The majority of the 
patients in this project went to the ED between three to six times in one year. Although it was 
difficult to establish an exact visit reason for ED presentation for the sample, all were treated as 
though they were having an exacerbation. This warrants concern as Duero Posada et al. (2018) 
report that multiple ED visits within a six to twelve month period increase the risk for poor 
outcomes and mortality.  
Frequency of ED visits for HF have been related to inadequate outpatient care 
management (Hasegawa, Tsugawa, Camargo, & Brown, 2014). In this project, the number of 
missed appointments was associated with the number of ED visits. These results highlight the 
problem with follow-up from the ED to the outpatient setting. Even in those that attended a 
follow-up appointment, approximately 20 percent did not have their recent ED/hospital visit 
discussed. This is consistent within the literature where there is a need for better systems to 
facilitate transitions of care knowing that acute exacerbations of HF are considered preventable 
through appropriate disease management (Blecker, Ladapo, Doran, Goldfeld, & Katz, 2014; 
Duero Posada et al, 2018). One clear example of this were the differences noted between the 
inpatient and outpatient medication reconciliation records. This has a broad range of 
consequences for providers and patients, as it may ultimately contribute to acute exacerbations 
rather than preventing them.   
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As almost 90 percent of the sample was hospitalized, it was important to look at length of 
stay to help determine appropriateness for potential outpatient IV diuretic therapy. Almost half of 
the patients in the sample had a LOS of two or less days. Patients with a LOS of two or less days 
had fewer comorbidities and attended their follow-up appointments. Prompt follow-up after ED 
visit has been shown to decrease readmissions and disease morbidity (Duero Posada et al, 2018). 
This group may potentially be amenable for outpatient IV diuretic therapy. In contrast, those 
with a LOS of three or more days had significantly more comorbidities and as reported by Duero 
Posada et al. (2018), adds to the complexity of disease management. The significant 
comorbidities common among this group were chronic pain, mood disorder, pulmonary 
hypertension, renal disease, and thyroid disease. Patients with HF and these comorbidities may 
not be appropriate for outpatient treatment of fluid overload with IV therapy. 
Those with fewer comorbidities may be amenable to outpatient IV diuretic therapy as 
their HF is less likely complicated by other illnesses. Patients typically not considered 
appropriate for outpatient IV diuresis include those with a concern for acute cardiac event or 
advanced renal failure.  Typically, patients with decompensated HF (reduced or preserved EF) 
can be seen in the outpatient setting if they are hemodynamically stable, resistant to oral 
medications, report symptoms of overload, and have evidence of hypervolemia on exam 
(Lazkani & Ota, 2012).  
The literature is inconsistent with a conclusion as to whether certain lab markers are 
important when considering which patients may be eligible for outpatient IV diuretic therapy 
(Ullo, M., & Sugalski, G., 2019). There were no other significant associations found between 
any collected lab values compared to LOS groups in the project sample. These results may 
support that certain lab markers may not be necessary to obtain prior to considering a patient 
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appropriate for outpatient treatment. Although the majority of the sample had a reduced EF, 
many outpatient models of IV diuretic therapy show no difference in outcomes between the two 
groups (Buckley et al., 2016). Individuals with preserved or reduced EF may be eligible to be 
treated as outpatients for fluid overload symptoms.  
The patient-related factors that can help reduce heart-failure related ED visits are 
medication therapy and lifestyle modifications (Ullo & Sugalski, 2019). These were assessed 
through discharge instructions at time of ED discharge and follow-up. The most common 
recommendations at ED or hospital discharge were provider medication compliance (93%) and 
follow-up (89%). There were varying inconsistencies among documentation of treatment 
recommendations and medications, making it difficult to assess if these were adequately 
addressed in the sample population. Most patients in the sample saw their cardiology provider 
for follow-up, though PCPs were also listed for follow-up. Having multiple providers often leads 
to mismanagement of disease processes (Rich, Lipson, Libersky, & Parchman, 2012). It is 
critical that one provider be identified as primarily managing the condition.  
Medicare continues to reduce reimbursement for readmissions for certain conditions, 
with 83 percent receiving a penalty in the most recent reports. These cuts could cost hospitals an 
estimated $563 million (Rau, 2019). Almost 20 percent of the sample population had a previous 
HF admission within 30 days of the initial encounter date. There were no associations found 
between 30-day HF readmissions and pre-ED or post- ED appointment attendance with a PCP or 
cardiology provider or with LOS days. Attention needs to be paid to the prevention of 
readmissions in those with HF.  
In examining patient characteristics that would be appropriate for outpatient IV diuresis, 
it is also important to have support from both ED and Cardiology providers. There were several 
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general themes identified from the interviews. ED providers were not comfortable with the long-
term management of HF and have difficulty with deciding dispositions, leading to more hospital 
admissions. In this project, exacerbations were noted to be due to a variety of factors.  These 
factors were most often medication or dietary noncompliance, social factors, and the cyclical 
nature of the disease was found. 
Providers agree that outpatient management needs improvement and that there is a 
potential patient population that could have their exacerbations treated in the outpatient setting.  
Ziaeian and Fonarow (2016) emphasized the importance of consistent follow-up with a HF 
provider. They report this significantly decreases the number HF exacerbations seen in the ED. 
The most important step to preventing mild to moderate HF exacerbations is to identify those 
that have manageable problems with outpatient treatment compliance. The barriers noted for 
establishing an outpatient model of IV diuretic therapy were consistent with the literature and 
included lack of space, staff, support from administration and patient interest (Buckley et al., 
2016).  Overall, improving the continuity of care among this HF population is important to 
reduce ED utilization and hospital admissions.  
Implications for Practice, Education, and Future Research 
 
Medicare has challenged hospital systems to focus on ways to reduce readmissions. 
Concerns have been raised by hospital administrators about the difficulty to create programs that 
actually produce better outcomes. Reducing unnecessary hospital admissions for HF will not be 
effective if the responsibility is placed solely on the inpatient setting. It is essential that 
ambulatory care clinics and hospitals work together to ensure their patients are receiving 
necessary care.      
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In the setting for which this project took place, there is not currently a way for patients to 
receive IV diuretic therapy on an outpatient basis. There are differences in the literature 
regarding the most reasonable strategy for ambulatory diuretic administration to prevent ED 
utilization (Buckley et al., 2016). Future research would include the assessment of current 
outpatient IV diuretic clinic models and their efficacy.  
It is necessary to examine the patient’s experience of their disease. Outpatient options for 
IV diuretic therapy have been shown to be well-utilized by HF patients for overload symptoms. 
The results of this project show the potential for a group of patients that would be eligible. It 
would be helpful to assess the patients’ perspective on utilization of an outpatient clinic. The 
hallmark of HF is symptom classification, which are described by the patient.  
The literature suggests that markers commonly assessed in the ED that are associated 
with morbidity in HF are renal dysfunction, hypotension, hyponatremia, elevated BNP, and 
elevated troponin. These may need to be reviewed in combination with clinical presentation to 
make a decision on whether a patient is appropriate for outpatient treatment of volume overload 
(Ullo, M., & Sugalski, G., 2019). Focusing on those with fewer comorbidities would be the 
starting point in identifying those that could receive outpatient IV diuresis.  
 It would be important to evaluate PCP opinion as many of these providers do primarily 
manage HF for some of their patients. Their threshold for considering a patient appropriate for 
outpatient IV diuretic therapy may be lower than other providers due to their lack of experience 
with the condition. The lack of consistent medication reconciliation adds to the complexity of 
treatment management. This encompasses 50 percent of the recommended treatment regimen 
and emphasizes the need for follow-up post-ED or hospital discharge, where the discharge 
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instructions are specifically addressed. This may be accomplished by having a focused provider 
along with a transitions of care team for this population.  
Limitations 
There were a few limitations to this project. While completing the chart review for the 
sample, it was difficult to establish the specific symptoms that initiated the patient going to the 
ED. This would have been helpful in further identifying those that may be eligible for outpatient 
IV diuresis. For example, one presenting with chest pain would need to be evaluated differently 
than one with increased swelling. Information on appointment history and follow-up education 
was unable to be obtained on patients that had an out-of-network PCP or cardiology provider 
because of the limited access to one EHR system. This would have provided a complete picture 
of the sample.  
Although marital status was investigated, the results did not support an understanding of 
the sample’s social support system. Social support can help individuals with HF have better 
disease management. The specific lab markers that were reviewed for the sample were chosen in 
an attempt to form a more complete clinical picture. The lab markers were only obtained at one 
time point during the project period, which may have limited the ability to analyze their specific 
impact on the disease management of the sample population.  
Although the primary residential location of each subject in the sample was obtained, it 
would have been helpful to further examine the characteristics of each area. The distance of the 
patient to a hospital and availability of local services would have been informative when 
considering why the sample utilized certain resources. The burden of HF disease within this 
sample population was not exclusively studied. Examining disease burden would have helped 
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quantify the morbidity of HF and led to more informative conclusions about the impact that 
outpatient IV diuretic therapy could have.  
Although the sample population was assessed for the presence of a general mood 
disorder, depression was not explicitly examined. Depression is relatively common among 
patients with HF and contributes to disease burden and poor outcomes (Mbakwem, Aina, & 
Amadi, 2016). Assessing for the prevalence of depression specifically would have contributed to 
the overall picture of this sample and may have revealed the need for more attention to its impact 
on the HF population.   
It would have been helpful to identify the symptom classifications of HF (I-IV) for each 
patient within the sample population. It was difficult to assess for classifications because of a 
lack of consistent documentation in the EHR. Treatments for HF are typically targeted based on 
these classes. For example, aggressive prevention of worsening heart function is typically the 
focus in Class I or II , where palliative care or more conservative approaches might be utilized 
for patients with Class III or IV HF.  
Conclusion 
 The results of this project revealed the potential for a group of patients with HF to be 
treated for fluid overload symptoms with IV diuretic therapy in the outpatient settings, 
specifically those with a LOS of two days or less. The patients in this sample were found to have 
inconsistences in follow-up appointment attendance, discharge and disease management 
instructions, and medication records. These issues result in disease mismanagement and could 
specifically contribute to HF exacerbations and contribute for readmissions and worsening 
disease morbidity. Interviews from ED and cardiology providers reiterated these results and 
stressed the need for more synchronized transitions from the hospital to outpatient setting. Future 
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research should focus on efforts to prevent hospitalizations and to provide more coordinated care 
for patients with HF.  
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Appendices  
Appendix A:  
Data Collection Tool  
Measures  Description Level of 
Measurement 
Data Source  
Demographics 
Gender Male v. Female Nominal Medical Record 
Ethnicity White, Black, Hispanic, Indian, 
Native American, Middle Eastern, 
Asian, Other 
Nominal Medical Record 
Age Age in years Interval/Ratio Medical Record 
Insurance  Passport, Private, Medicaid, 
Medicare, Other, Self-Pay 
Ordinal Medical Record  
Outcome Measures  
ED visits Number of patients with HF seen 
in ED 
Quantitative  Medical Record  
Length of 
Hospital 
Stay 
Length of stay in days, based on 
admission and discharge days  
Quantitative Medical Record  
Number of 
patients that 
received IV 
Diuretics 
Number of patients with ADHF 
that are given IV diuretics  
Quantitative Medical Record 
# of 30 day 
HF 
readmissions 
Number of patients with ADHF 
that have at least 2 hospital 
admissions within a 30-day time 
period  
Quantitative Medical Record 
Selected Project ICD 10/CPT codes  
I50.23  Acute on chronic systolic 
(congestive) heart failure 
  
I50.33 Acute on chronic diastolic 
(congestive) heart failure 
  
I50.43 Acute on chronic combined 
systolic (congestive) and diastolic 
(congestive) heart failure 
  
I50.813 Acute on chronic right heart failure    
E87.70 Hypervolemia/fluid overload   
J1940 Furosemide injection   
Z95.811 CPT/ICD codes for LVAD present is    
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Appendix B: 
Email to Providers 
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Appendix C: 
Provider Consent Form  
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Appendix D: 
Provider Interview Guide 
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Appendix E: 
Table of Sample Demographics  
Table of Demographics for Sample Population.  
Demographics Mean (SD) or n (%) 
Age 66  
Gender 
   Male 
   Female 
 
49 (49%) 
51 (51%) 
Race 
    Caucasian 
    Black 
    Hispanic   
 
74 (74%) 
22 (22%) 
Location 
     Local (Fayette County) 
     Non-local (Outside of Fayette County)  
 
63 (63%) 
47 (47%) 
Marital Status 
     Single 
     Married 
     Divorced 
     Widowed/Separated 
 
13 (13%) 
47 (47%) 
13 (13%) 
27 (27%) 
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Appendix F: 
Table of Selected Comorbidities  
Table of Selected Comorbidities for Sample Population 
Comorbidities  Percentage of Sample  
Arrythmia 58% 
Hyperlipidemia 61% 
Congestive Heart Failure 
(CHF) 
              Unspecified CHF 
              Systolic CHF 
              Diastolic CHF 
100% 
24 % 
51% 
25% 
Chronic Pain 15% 
COPD 32% 
Diabetes (all types) 53% 
Hypertension 87% 
AICD/ Pacemaker 22% 
Myocardial Infarction 20% 
Mood Disorder  30% 
Obstructive Sleep Apnea 20% 
Thyroid Disease 20% 
Valve Replacement 14% 
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Appendix G: 
Initial Lab Markers for ED Encounter for Sample 
 
Table of Descriptive Statistics for Initial ED Labs for Sample.  
 N Minimum Maximum Mean Std. 
Deviation 
Last BP diastolic 99 38 116 78.26 16.452 
BP systolic 99 87 178 132.31 21.239 
Potassium 99 2.6 6.0 4.204 .6608 
CR 99 .59 7.09 1.4344 .86762 
A1C 87 4.5 12.9 6.560 1.6298 
NT-pro BNP 99 164 52391 8149.34 10379.472 
GFR 91 6 60 46.01 13.250 
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Appendix H:  
Summary of Common Medications for the Sample (percent of sample prescribed medication) 
 Discharge Medications Outpatient Medications 
Thiazide Diuretics 5% 18% 
Loop Diuretic 44% 68% 
Potassium Sparing Diuretic 11% 20% 
Beta Blocker  50% 66% 
ACE/ARB 24% 56% 
Calcium Channel Blocker 5% 26% 
Hydralazine 7% 9% 
Statin Medication 34% 13% 
Mood Adjustment Drug 4% 7% 
 
 
